Open AccessPHARMACOLOGIC ACTIVATION OF THE ALTERNATIVE RAS ATTENUATES DEVELOPMENT OF PULMONARY ARTERIAL HYPERTENSION IN MONOCROTALINE TREATED RATS
Author(s) -
Benjamin Vigl,
Simona Trubacova,
Marko Poglitsch,
Oliver Domenig,
Peter Bališ,
Andrej Barta,
Pavol Valovic,
Silvia Líšková,
Fedor Šimko,
Ľudovít Paulis
Publication year - 2021
Publication title -
journal of hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.249
H-Index - 172
eISSN - 1473-5598
pISSN - 0263-6352
DOI - 10.1097/01.hjh.0000748560.08337.80
Subject(s) - bosentan , medicine , ventricle , pulmonary hypertension , ambrisentan , blood pressure , cardiology , pulmonary heart disease , endothelin receptor , angiotensin ii , pressure overload , endothelin receptor antagonist , concomitant , ventricular pressure , pulmonary arterial pressure , heart failure , receptor , cardiac hypertrophy